CAS 545380-34-5: N~4~-[2-(4-phenoxyphenyl)ethyl]quinazoline-4,6-diamine

Applications QNZ is a novel inhibitor of NFkB which displays potent inhibitory effects on both NFKB transcriptional activation (IC50=11nM) and TNF-α production (IC50=7nM). It dose-dependently inhibited carragenin-induced edema formation in the rat paw model (1mg/Kg). A useful tool to explore the role of NFkB in cellular signaling pathways. References Tobe, M., et al.: Bioorg. Med. Chem., 11, 3869 (2003), Choi, S., et al.: J. Biol. Chem., 281, 12722 (2006)

QNZ (EVP4593) (EVP4593) is an effective inhibitor of NF-κB activation and TNF-α production. The IC50 of QNZ for NF-κB and TNF-α is11 nM and 7 nM, respectively.

QNZ

6-Amino-4-(4-phenoxyphenylethylamino)quinazoline is a potential anticancer drug that has been shown to inhibit the polymerase chain reaction in human osteosarcoma cells. It also inhibits the signaling pathway of nuclear factor-κB (NF-κB), which is involved in cell death and tumorigenesis. 6-Amino-4-(4-phenoxyphenylethylamino)quinazoline has shown significant cytotoxicity against murine hepatoma cells and bowel disease cells, but not against normal tissue. This drug is also an inhibitor of the drug transporter Pgp. 6-Amino-4-(4-phenoxyphenylethylamino)quinazoline has been shown to be effective in experimental models for cancer, AIDS, and other infectious diseases.